Leaderboard
Anzeige
medline.ch
En
|
De
Impressum
No articles selected!
View Cart
You are here:
Oncology
»
Urologic Neoplasms
15. June 2026
Search
medline.ch
Urologic Neoplasms
Advanced search
Dermatology
Endocrinology
Nutrition
Gastroenterology
Gynecology
Haematology
Infectious diseases
Cardiovascular Diseases
Musculoskeletal Diseases
Neurology
Oncology
Musculoskeletal System
Blood
Endocrine System
Gynecologic Neoplasms
Skin
Gastrointestinal
ORL
Respiratory Tract
Urologic Neoplasms
CNS
ORL
Pediatrics
Psychiatry
Respiratory Tract
Sports
Urology-Nephrology
Rect Top
Anzeige
Zoom:
Page 1 of 8951
Articles 1 - 20 / 179016
Patient-Reported Outcomes on Quality of Life and Psychological Distress After Focal High-Intensity Focused Ultrasound for Prostate Cancer: Prospective Multicenter Study.
JMIR Cancer
Franz T, Hartung C, Ganzer R, Holze S, Stolzenburg JU.
PMID: 42295325 [PubMed - indexed for MEDLINE]
Preliminary clinical association between the Nerve-Sparing Quality (NSQ) Score and early functional outcomes after robot-assisted radical prostatectomy.
Folia Med Cracov
Kempisty J, Balawander K, D, Burdziak K.
PMID: 42295074 [PubMed - indexed for MEDLINE]
Intraoperative Hypotension During Photodynamic Diagnosis-Guided TURBT Under Spinal Anesthesia: A Propensity Score-Matched and Logistic Regression Analysis.
Int J Urol
Igarashi A, Kinoshita T, Fujita M, Obayashi R, Yamamoto A, Yamamoto R, Akagi N, Shibasaki N, Kawakita M, Yamasaki T.
PMID: 42295047 [PubMed - indexed for MEDLINE]
TURBT versus RC in T1N0M0 non-urothelial bladder cancer: a population-based study.
Front Oncol
He Q, Chen Y, Zhang T, Sheng W, Huang J.
PMID: 42294298 [PubMed]
Development and validation of a machine learning-based radiomics model using 45-keV virtual monoenergetic images for differentiating fat-poor angiomyolipoma from clear cell renal cell carcinoma.
Transl Androl Urol
Jing S, Wang J, Zhao X, Zeng B, Luo J, Yang Z, Liu Y.
PMID: 42293856 [PubMed]
Future direction of systemic therapy for advanced renal cell carcinoma: lessons from final and extended follow-up data from the CheckMate 9ER trial.
Transl Androl Urol
Ishihara H.
PMID: 42293852 [PubMed]
Electrolyte trajectory-based subphenotypes and their association with hospital length of stay in prostate cancer patients.
Transl Androl Urol
Shen Y, Xuan H, Wang J, Hu Y, Zhang Y.
PMID: 42293848 [PubMed]
Diagnostic potential of urinary PENK methylation for bladder cancer in patients with hematuria: insights from a prospective and multi-institutional study.
Transl Androl Urol
Koguchi D, Shiba I, Shiono Y, Matsumoto K.
PMID: 42293844 [PubMed]
Analysis of factors affecting the upstaging and downstaging of renal cell carcinoma from T1 to T3a and the impact of different surgical approaches on patient prognosis and survival: a multicenter retrospective study.
Transl Androl Urol
Zhang Y, Baerbieke Y, Fan J, Ma C, Zhuang Y, Li J, Wang Z, Zeng J, Shi X, Yang T, Pei X, Li X.
PMID: 42293838 [PubMed]
Association between prognostic nutritional index (PNI)/Controlling Nutritional Status (CONUT) score and prognosis in patients with bladder cancer: a systematic review and meta-analysis.
Transl Androl Urol
Chen Y, Zheng J, Li D, Wu Q, Ren Q.
PMID: 42293833 [PubMed]
Utilizing intraoperative frozen section examination (IFSE) for diagnosis and treatment in a high-clinical-suspicion prostate cancer (PCa) cohort based on (18)F-PSMA PET/CT and MRI: a pilot study.
Transl Androl Urol
Zhu LY, Fang M, Luan Y, Huang TB, Lu SM, Xiao Q, Chen J, Tan X, Ding XF.
PMID: 42293831 [PubMed]
Site-specific heterogeneity in treatment response among patients with metastatic bladder cancer: implications for oligometastatic disease-a retrospective cohort study.
Transl Androl Urol
Wang T, Wei B.
PMID: 42293828 [PubMed]
Dietary patterns and knowledge-attitude-practice factors are associated with late recurrence of non-muscle-invasive bladder cancer: a case-control study.
Front Nutr
Wu Q, Qing X, Gao W.
PMID: 42293220 [PubMed]
Determining the Correlation and Effect of Rectal and Bladder Volume Change in Shift of Planning Target Volume and Calculating Planning Target Volume Margin with Van Herk Formula in Prostate Cancer Tomotherapy.
J Biomed Phys Eng
Shabaninejad V, Shanei A, Roayaei M, Akhavan A, Saeb M, Hadinezhad S.
PMID: 42292680 [PubMed]
From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer.
Front Immunol
Jin M, Cai Z, Bu M, Liu J, Zhang X.
PMID: 42292383 [PubMed - indexed for MEDLINE]
Pulmonary Fibrosis and Pulmonary Function in Patients with Metastatic Testicular Cancer During and after Combination Chemotherapy: The BLEOTOX Study.
Eur Urol Open Sci
Frey L, Grunwald S, Ruckes C, Duwe G, Wohlleber K, Frey LJ, Haack M, Rölz N, Dotzauer R, Korczynski D, Axel Haferkamp A, Brandt MP.
PMID: 42291633 [PubMed]
Next-generation imaging in prostate cancer.
Front Urol
Rabie A, Buscarini M, Zaytoun O.
PMID: 42291630 [PubMed]
Bone remodeling: a central mechanism in prostate cancer bone metastasis.
PeerJ
Tang H, Chen J, Wu H, Lv Y, Wa Q, He S.
PMID: 42291433 [PubMed - indexed for MEDLINE]
N-glycosylation alterations in expressed prostatic secretions: exploring liquid biopsy biomarkers for prostate cancer diagnosis and disease progression.
PeerJ
Chew IYY, Jayapalan JJ, Lim J.
PMID: 42291429 [PubMed - indexed for MEDLINE]
Predictive model validation of new baseline renal function in southern Chinese patients after partial or radical nephrectomy.
PeerJ
Li J, Zhai G, Xie Y, Yan XY, Qin Y, Liu BF, Tan ST, Gan QH, Wang W.
PMID: 42291427 [PubMed - indexed for MEDLINE]
Articles 1 - 20 / 179016
Page 1 of 8951
Rect Bottom
Anzeige
Adserver Footer
Time frame
--unlimited--
1 Week
1 Month
3 Months
6 Months
1 Year
2 Years
3 Years
5 Years
10 Years
Sky right 1
Anzeige
Mediscope AG E-mail:
info@mediscope.ch
Disclaimer
|
Privacy Policy